Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
{{output}}
Purpose: Tinengotinib, a multikinase inhibitor targeting Aurora kinases A/B, fibroblast growth factor receptors (FGFRs) 1-3, vascular endothelial growth factor receptor-2, and Janus kinases 1-2, was evaluated in this phase Ib/II ... ...
